APLNR Antibody (MM0095-7D4): sc-517458
- APLNR Antibody (MM0095-7D4) is a mouse monoclonal IgG3 provided at 100 µg/ml
- raised against a recombinant protein corresponding to APLNR of human origin
- recommended for detection of APLNR of human origin by WB, IF and IHC(P)
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for APLNR Antibody (MM0095-7D4). This work is in progress.
QUICK LINKS
SEE ALSO...
APLNR Antibody (MM0095-7D4) is a mouse monoclonal IgG3 antibody that detects apelin receptor (APLNR) in human samples through applications such as western blotting (WB), immunofluorescence (IF), and immunohistochemistry. Anti-APLNR antibody (MM0095-7D4) recognizes a G protein-coupled integral membrane protein predominantly located in the hypothalamus, where APLNR plays a crucial role in regulating various physiological processes, including fluid balance and cardiovascular function. APLNR is activated by its endogenous ligand, apelin, which not only promotes receptor internalization but also modulates intracellular signaling pathways, such as the inhibition of forskolin-induced cyclic adenosine monophosphate (cAMP) production. Studies have shown that APLNR internalization is not strictly necessary for hypotensive effects, indicating that APLNR may operate through multiple conformational states to elicit different biological responses. APLNR has been implicated in the regulation of hypothalamic function under stress conditions, as APLNR is negatively regulated by glucocorticoids. APLNR serves as an alternative coreceptor for HIV-1 infection, highlighting APLNR significance in both neurobiology and virology. APLNR monoclonal antibody (MM0095-7D4) is an essential tool for researchers investigating the diverse roles of this receptor in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
APLNR Antibody (MM0095-7D4) References:
- ERG-APLNR axis controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive disease. | Lathen, C., et al. 2014. Circulation. 130: 1179-91. PMID: 25062690
- Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelin's glucose-lowering effects. | Hwangbo, C., et al. 2017. Sci Transl Med. 9: PMID: 28904225
- Apelin receptor (Aplnr) signaling promotes fibroblast migration. | Doğan, A. 2019. Tissue Cell. 56: 98-106. PMID: 30736911
- APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling. | Liu, Y., et al. 2019. FASEB J. 33: 11959-11972. PMID: 31408612
- APLNR stimulates the development of glioma via the NFAT5/AKT feedback loop. | Zhang, ZP., et al. 2020. Eur Rev Med Pharmacol Sci. 24: 10594-10600. PMID: 33155216
- Modulation of APLNR Signaling Is Required during the Development and Maintenance of the Hematopoietic System. | Jackson, M., et al. 2021. Stem Cell Reports. 16: 727-740. PMID: 33667414
- APLN/APLNR Signaling Controls Key Pathological Parameters of Glioblastoma. | Kälin, RE. and Glass, R. 2021. Cancers (Basel). 13: PMID: 34359800
- APLNR Regulates IFN-γ signaling via β-arrestin 1 mediated JAK-STAT1 pathway in melanoma cells. | Liu, Y., et al. 2022. Biochem J. 479: 385-399. PMID: 35084016
- The Apelin/APLNR system modulates tumor immune response by reshaping the tumor microenvironment. | Yang, Y., et al. 2022. Gene. 834: 146564. PMID: 35598689
- APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1. | Liu, Y., et al. 2024. Int Immunopharmacol. 137: 112523. PMID: 38909500
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
APLNR Antibody (MM0095-7D4) | sc-517458 | 100 µg/ml | $322.00 |